AU2001233957A1 - Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (bad) and unipolar depression - Google Patents
Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (bad) and unipolar depressionInfo
- Publication number
- AU2001233957A1 AU2001233957A1 AU2001233957A AU3395701A AU2001233957A1 AU 2001233957 A1 AU2001233957 A1 AU 2001233957A1 AU 2001233957 A AU2001233957 A AU 2001233957A AU 3395701 A AU3395701 A AU 3395701A AU 2001233957 A1 AU2001233957 A1 AU 2001233957A1
- Authority
- AU
- Australia
- Prior art keywords
- genes
- diagnosis
- bad
- proteins
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/304—Mood disorders, e.g. bipolar, depression
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0004412 | 2000-02-24 | ||
GB0004412A GB0004412D0 (en) | 2000-02-24 | 2000-02-24 | Proteins and their use for diagnosis and treatment of bipolar affective disorder and unipolar depression |
GB0030050A GB0030050D0 (en) | 2000-12-08 | 2000-12-08 | Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (BAD) and unipolar depression |
GB0030050 | 2000-12-08 | ||
US25483000P | 2000-12-12 | 2000-12-12 | |
US60254830 | 2000-12-12 | ||
PCT/GB2001/000791 WO2001063294A2 (en) | 2000-02-24 | 2001-02-23 | Diagnosis of bipolar affective disorder (bad) and unipolar depression |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001233957A1 true AU2001233957A1 (en) | 2001-09-03 |
Family
ID=27255558
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001233957A Abandoned AU2001233957A1 (en) | 2000-02-24 | 2001-02-23 | Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (bad) and unipolar depression |
AU2001233955A Abandoned AU2001233955A1 (en) | 2000-02-24 | 2001-02-23 | Diagnosis and treatment of bipolar affective disorder |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001233955A Abandoned AU2001233955A1 (en) | 2000-02-24 | 2001-02-23 | Diagnosis and treatment of bipolar affective disorder |
Country Status (3)
Country | Link |
---|---|
EP (2) | EP1259819A2 (en) |
AU (2) | AU2001233957A1 (en) |
WO (2) | WO2001063294A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7314762B2 (en) | 2001-11-21 | 2008-01-01 | Nanogen, Inc. | Apolipoprotein biopolymer markers indicative of insulin resistance |
US7052849B2 (en) | 2001-11-23 | 2006-05-30 | Syn X Pharma, Inc. | Protein biopolymer markers predictive of insulin resistance |
US20030113808A1 (en) * | 2001-12-13 | 2003-06-19 | George Jackowski | Apolipoprotein biopolymer markers predictive of alzheimers disease |
DE10225144A1 (en) * | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding to MHC molecules |
DE60322719D1 (en) * | 2002-08-23 | 2008-09-18 | Bayer Healthcare Ag | POLYPEPTIDE BIOMARKERS FOR THE DIAGNOSIS OF MORBUS ALZHEIMER |
EP1394549A1 (en) | 2002-08-23 | 2004-03-03 | Bayer HealthCare AG | Biomarkers for diagnosing Alzheimer's disease |
ES2286543T3 (en) | 2003-04-17 | 2007-12-01 | Affectis Pharmaceuticals Ag | MEANS AND METHODS TO DIAGNOSE AND TREAT AFFECTIVE DISORDERS. |
KR101219519B1 (en) * | 2011-05-06 | 2013-01-09 | 한국기초과학지원연구원 | A method for the diagnosis using lectin |
RU2488118C1 (en) * | 2011-11-21 | 2013-07-20 | Учреждение Российской Академии Медицинских Наук Научно-Исследовательский Институт Психического Здоровья Сибирского Отделения Рамн | Method for prediction of formation of organic personality disorder |
CN110361242B (en) * | 2019-08-14 | 2022-01-18 | 武汉赛维尔生物科技有限公司 | Fixing liquid for eyeball tissue and pretreatment method for preparing eyeball tissue slices |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU648505B2 (en) * | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
JPH11507845A (en) * | 1997-02-13 | 1999-07-13 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Neural cell adhesion molecule splicing variant |
US5866412A (en) * | 1997-03-27 | 1999-02-02 | Millennium Pharmaceuticals, Inc. | Chromosome 18 marker |
AU8580598A (en) * | 1997-07-22 | 1999-02-16 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders |
KR100626475B1 (en) * | 1997-10-24 | 2006-09-20 | 아방티 파르마 소시에테 아노님 | Peptides capable of inhibiting the interaction between presenilins and the ?-amyloid peptide or its precursor |
WO1999035290A1 (en) * | 1998-01-08 | 1999-07-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
US20070004655A9 (en) * | 1998-04-27 | 2007-01-04 | Murphy Gerald P | Nr-cam gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors |
CA2332109A1 (en) * | 1998-05-12 | 1999-11-18 | Human Genome Sciences, Inc. | 97 human secreted proteins |
PT1609863E (en) * | 1999-03-23 | 2009-01-02 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
-
2001
- 2001-02-23 WO PCT/GB2001/000791 patent/WO2001063294A2/en not_active Application Discontinuation
- 2001-02-23 EP EP01905998A patent/EP1259819A2/en not_active Withdrawn
- 2001-02-23 AU AU2001233957A patent/AU2001233957A1/en not_active Abandoned
- 2001-02-23 AU AU2001233955A patent/AU2001233955A1/en not_active Abandoned
- 2001-02-23 WO PCT/GB2001/000786 patent/WO2001062787A1/en not_active Application Discontinuation
- 2001-02-23 EP EP01905994A patent/EP1259539A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2001063294A2 (en) | 2001-08-30 |
WO2001062787A1 (en) | 2001-08-30 |
WO2001063294A3 (en) | 2002-04-11 |
EP1259819A2 (en) | 2002-11-27 |
AU2001233955A1 (en) | 2001-09-03 |
EP1259539A1 (en) | 2002-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002216273A1 (en) | Proteins, genes and their use for diagnosis and treatment of kidney response | |
AU2003275029A1 (en) | Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues | |
MXPA02011656A (en) | Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods. | |
EP2332955A3 (en) | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression | |
EP2253706A3 (en) | Antisense modulation of kinesin-like 1 expression | |
HUP0301246A2 (en) | Human coagulation factor vii variants | |
EP1461352A4 (en) | Antisense modulation of connective tissue growth factor expression | |
CA2257133A1 (en) | Human dnase i hyperactive variants | |
AU4882296A (en) | DNA molecules, preparation and use in gene therapy | |
WO2001070977A3 (en) | Fibroblast growth factor receptor-like molecules and uses thereof | |
AU2002251366A1 (en) | Proteins, genes and their use for diagnosis and treatment of breast cancer | |
AU2001233957A1 (en) | Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (bad) and unipolar depression | |
AU2001240909A1 (en) | Proteins, genes and their use for diagnosis and treatment of breast cancer | |
AU2002330215A1 (en) | Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease | |
WO2003023004A3 (en) | Antisense modulation of fibroblast growth factor receptor 3 expression | |
WO2003014306A3 (en) | Antisense modulation of cholesteryl ester transfer protein expression | |
AU6583700A (en) | Proteins, genes and their use for diagnosis and treatment of breast cancer | |
AU2002258728A1 (en) | Gene brcc-3 and diagnostic and therapeutic uses thereof | |
AU2002305151A1 (en) | Gene scc-112 and diagnostic and therapeutic uses thereof | |
AU2001233954A1 (en) | Proteins, genes and their use for diagnosis and treatment of schizophrenia | |
WO2004043394A3 (en) | Modulation of huntingtin interacting protein 1 expression | |
EP2270230A3 (en) | Antisense modulation of insulin-like growth factor binding protein 5 expression | |
GB0030050D0 (en) | Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (BAD) and unipolar depression | |
AU2001240820A1 (en) | Proteins, genes and their use for diagnosis and treatment of vascular dementia | |
WO2003070878A3 (en) | Antisense modulation of hematopoietic cell protein tyrosine kinase expression |